ReviewFrontiers in oncology2019
The Role of Metabolic Syndrome in Endometrial Cancer: A Review.
Review in Frontiers in oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 4 syntheses or guidelines pooled it, 155 citations in OpenAlex.
- Risk of gynaecologic cancers in women with metabolic syndrome: A systematic review & meta-analysis.The Indian journal of medical research · 2025Pooled it
- The relationship between metabolic syndrome and survival of patients with endometrial cancer: a meta-analysis.Frontiers in oncology · 2024Pooled it
- Systematic review of Mendelian randomization studies on risk of cancer.BMC medicine · 2022Pooled it
- Pooled it
- Development and validation of a prognostic model based on metabolic risk score to predict overall survival of endometrial cancer in Chinese patients.Journal of gynecologic oncology · 2023Trial
- Associations of novel adiposity indices with gynecological cancer risk among adult women: Evidence from NHANES 2011 to 2018.Medicine · 2026Article
- Article
- Fats and Facts: A Meta-Analysis of Lipid Biomarkers in Endometrial Cancer.Life (Basel, Switzerland) · 2026Review
- Profiling Sociodemographic Risk Factors and Clinical Outcomes of Women with Endometrial Cancer in Puerto Rico: The Central Role of Obesity and Obstetric Features.Journal of racial and ethnic health disparities · 2026Article
- Lactate transmission from hypoxic tumor cells promotes macrophage senescence and M2 polarization via the DNMT1-NHE7 axis to accelerate endometrial cancer progression.Cell death & disease · 2026Article
- A clinically translatable pathomics-based predictive model for preoperative prognostic assessment in patients with endometrial cancer.Discover oncology · 2026Article
- Lifestyle, Modifiable Behavioral Factors, and Biomarker Profiles in Uterine Lesions.Healthcare (Basel, Switzerland) · 2026Article
- Circulating miRNA as diagnostic tools for gynecological diseases and their applications in biosensor development.Analytical and bioanalytical chemistry · 2026Review
- Alterations in lipid metabolism and blood profile in gynecological cancers - potential strategies in diagnosis and treatment.Frontiers in physiology · 2026Review
- Explainable machine learning for preoperative relapse prediction in molecularly stratified endometrial cancer: A single-center finnish cohort study.Computational and structural biotechnology journal · 2026Article
- Physical activity as a molecular modulator to enhance immunotherapy and drug sensitivity in the endometrial cancer-comorbidity continuum.Frontiers in oncology · 2026Review
- Metabolic syndrome promotes endometrial cancer by Oleic acid-mediated polyamine accumulation.Nature communications · 2025Article
- Development and validation of a machine learning-based pathomics nomogram for prognostic prediction in endometrial cancer.Discover oncology · 2025Article
- Diabetes, Obesity, and Endometrial Cancer: A Review.Current oncology (Toronto, Ont.) · 2025Review
- Adiposity, metabolites and endometrial cancer risk: inference from combinations of Mendelian randomization and observational analyses.BMC cancer · 2025Observational
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Endometrial cancer is one of the most common cancers of the female reproductive system. Although surgery, radiotherapy, chemotherapy, and hormone therapy can significantly improve the survival of patients, the treatment of patients with very early lesions and a strong desire to retain reproductive function or late recurrence is still in the early stages. Metabolic syndrome (MS) is a clustering of at least three of the five following medical conditions: central obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL). Obesity, diabetes and hypertension often coexist in patients with endometrial cancer, which increases the risk of endometrial cancer, also known as the "triple syndrome of endometrial cancer." In recent years, epidemiological and clinical studies have found that MS associated with metabolic diseases is closely related to the incidence of endometrial cancer. However, the key molecular mechanisms underlying the induction of endometrial cancer by MS have not been elucidated to date. Characterizing the tumor metabolism microenvironment will be advantageous for achieving a comprehensive view of the molecular mechanism of metabolic syndrome associated with endometrial cancer and for providing a new target for the treatment of endometrial cancer. This review focuses on recent advances in determining the role of metabolic syndrome-related factors and mechanisms in the pathogenesis of endometrial cancer. We suggest that interfering with the tumor metabolic microenvironment-related molecular signals may inhibit the occurrence of endometrial cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.